Penny Stocks For You List This Month
Penny shares are selecting up steam this month. Thanks to a relentless seek for volatility, these low cost shares are the shining gentle amid a sea of pink within the broader markets. Some might use ETFs just like the Russell Small-Cap ETF (NYSE:IWM) to gauge retail sentiment. But I’ll be the primary to let you know that doing that will skew actuality fully. The truth of the matter is that it doesn’t matter what broader markets or ETFs are doing, there’s certain to be at the very least just a few penny stocks to look at. It’s this actual purpose we are saying day merchants continuously hunt down the subsequent meme inventory or trending short-squeeze penny stocks to purchase.
PennyStocks.com – PennyStocks
Top Penny Stocks For You Watch List
Something to think about when studying any article about penny shares (even this one) is that volatility can change at a second’s discover. This implies that “today’s” development could also be fully completely different tomorrow. It additionally implies that having a eager understanding of how one can commerce shares, generally, will likely be essential. Assuming you’ve obtained your plan in place and a technique outlined, right here’s a list of penny stocks that merchants are watching this week.
- CASI Pharmaceuticals (NASDAQ:CASI)
- Ampio Pharmaceuticals (NYSE:AMPE)
- Clovis Oncology (NASDAQ:CLVS)
- Conformis Inc. (NASDAQ:CFMS)
- Eyegate Pharmaceuticals (NASDAQ:EYEG)
1. CASI Pharmaceuticals (NASDAQ:CASI)
Some insider shopping for late final month introduced retail consideration to CASI Pharmaceuticals. CEO Wei-Wu He picked up 480,000 shares between $1.26 and $1.29. This got here shortly after the corporate reported its second-quarter monetary outcomes and enterprise replace. Leading the income development for the quarter was the corporate’s EVOMELA. This is CASI’s multiple-myeloma therapy within the US. Based on this growth, CASI revised its steerage for the complete 12 months’s income development to greater than 80% in comparison with 2020.
Looking forward, CASI has begun dosing sufferers in its Phase 1 trial of the therapy CID-103 for relapsed or refractory a number of myeloma. The drug candidate beforehand demonstrated robust preclinical efficacy and security in preclinical exams. With a number of remedies in its pipeline, industrial development from EVOMELA, and ongoing trials to report information on, CASI inventory has been one to look at not too long ago.
Furthermore, from a technical perspective, a fast take a look at the chart additionally reveals that it continues to carry ranges above a serious technical stage, the 50-day transferring common. This has lengthy been a stage of fixed resistance this 12 months. The latest spike above this space might also have technical merchants monitoring the each day motion extra carefully.
2. Ampio Pharmaceuticals (NYSE:AMPE)
Ampio has adopted the development of GMVD after releasing information of its personal. In this case, the biotech firm reported top-line outcomes from its AP-013 Phase 3 research. This tracked progress within the firm’s Ampion therapy in sufferers affected by ache as a result of osteoarthritis within the knee.
Accordingly, the corporate defined that there was a “significant reduction” in ache and an improved operate after 12 weeks. CEO Mike Macaluso additionally added that “We will complete the analysis of the AP-013 study and present all data to the FDA with the goal of filing a BLA for Ampion.”
New analysis final month helped carry extra optimism to the potential of Ampion. In a analysis manuscript, “LMWF5A demonstrated an Anti-Inflammatory Mode of Action and Similar Drug Targets to Dexamethasone in Activated PBMC,” particulars surfaced. This confirmed that preclinical analysis completed on the mode of motion of Ampion demonstrated that it may very well be used to deal with circumstances supported for dexamethasone with “fewer or less harmful” uncomfortable side effects. With these newest developments, AMPE inventory has been one to look at over the previous few weeks.
3. Clovis Oncology (NASDAQ:CLVS)
One of the brief squeeze penny shares we’ve mentioned not too long ago is Clovis Oncology. While it hasn’t surged like its cohorts thus far, that doesn’t imply it hasn’t turn out to be some extent of focus for some. Based on latest figures, the brief float share for CLVS inventory sits at round 26%. Despite the general float being greater than 100 million shares, this share continues to be thought of excessive by most accounts.
The firm focuses on growing most cancers remedies. Clovis’ lead candidate, Rubraca, has additionally gotten some latest consideration. This therapy is being developed for quite a few most cancers tumor varieties. Ovarian and prostate are among the many completely different most cancers tumors. The therapy is already authorised within the US for upkeep therapy in adults with recurrent epithelial, ovarian, fallopian tubes, or main peritoneal cancers. Last month, Clovis introduced that Rubraca is now out there and reimbursed in Switzerland.
According to the corporate, with 3 part 3 read-outs for Rubraca within the subsequent “6-18 months,” the market seems to be cautiously targeted on what comes subsequent for the corporate. All that being mentioned, with pleasure surrounding “short squeeze stocks,” it may very well be one more reason why CLVS has turn out to be one of many penny stocks to watch proper now.
4. Conformis Inc. (NASDAQ:CFMS)
Conformis is in the midst of a circuit of investor displays this month. Earlier within the week, the corporate introduced at HC Wainwright’s Global Investment Conference. Next week, Conformis will likely be at Oppenheimer’s Healthcare Life Sciences & MedTech Summit.
The medical expertise firm develops joint substitute implants and devices custom-made for its purchasers. Its iFit Image-to-Implant expertise permits the corporate to individually measurement and form its personalized substitute implants for all sorts of sufferers.
It additionally not too long ago performed the primary “Identity Imprint” process. This is the corporate’s knee substitute system. “Identity Imprint integrates elements of personalized design with the convenience and flexibility of an off-the-shelf system, which is advantageous for surgeons and patients alike,” mentioned Mark Augusti, President and CEO of Conformis. With this progress, CFMS continues to be one of many medical system shares on the watch record proper now.
5. Eyegate Pharmaceuticals (NASDAQ:EYEG)
Eyegate was one of many penny shares we mentioned earlier this week. In that article (4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507%), we talked about how analysts have been bullish on EYEG inventory. Earlier this month, HC Wainwright analyst Yi Chen reiterated a Buy on the inventory and at present has an $11 value goal. But why is that this so bullish?
EyeGate not too long ago introduced that it completed its goal enrollment in a Phase 2 proof-of-concept research. The firm’s PP-001 therapy will likely be evaluated for ocular floor irritation. Further to this, topline information is anticipated subsequent quarter. There are additionally plans for submitting an Investigational New Drug submitting subsequent quarter for the therapy candidate.
With momentum as a tailwind, upcoming information to take a look at, and bullish analysts, EYEG may very well be one other one of many penny shares to look at this month.
Can You Make Money With Penny Stocks?
Making cash with penny shares is simpler mentioned than completed at occasions. However, as mentioned earlier, your plan issues. Have a technique in thoughts earlier than leaping into any commerce. If you’re model new, listed below are just a few articles that ought to assist get you began: